VOGX · NASDAQ · Healthcare · $300.8M
$20.25+1.7%vs prev closeclose of 2026-10-30 · not real-time
vs. analyst consensus target. The target is an opinion, not a prediction or buy signal.
Some axes lack data (–)
A summary of valuation factors — not a buy recommendation. You decide.
| Company | PER | PBR | ROE | Div | Score |
|---|---|---|---|---|---|
| Vogenx Inc | – | – | – | 0.0% | – |
| Sanara MedTech Inc. | – | 38.0 | -1% | 0.0% | 39 |
| Anika Therapeutics Inc. | – | 2.0 | -2% | 0.0% | 35 |
| Clinuvel Pharmaceuticals Limited | 11.3 | 1.3 | 13% | 0.7% | 58 |
| Spok Holdings Inc. | 13.6 | 1.7 | 13% | 10.6% | 76 |
| Fennec Pharmaceuticals Inc. | – | 8.5 | -19% | 0.0% | 39 |
Same sector, nearest by market cap · – = no data (value traps excluded)
The chart (long-term trend, Ichimoku cloud) is for observation only — not a buy or sell signal.
A highlight of the key metrics detailed below.
Top-tier in 0 of 1 evaluated strategies
Ranks within the US market — tap to open that ranking (ranks are per market).
Past returns — they do not guarantee future results.
EV as reported by our data provider (Yahoo Finance) · net debt is our own calc (total debt − cash) · definitions differ, so EV need not equal market cap + net debt (minority interest, preferred stock)
Color: green = healthy, red = caution (absolute thresholds, value/quality metrics only). Downside vol & Sortino are annualized. Max drawdown = largest drop from a 3-year peak; volatility = 1-year annualized. Price/Graham < 1 = below Graham fair value (profitable, positive-equity names only). RSI < 30 = oversold. For reference only.
A Japanese trend tool. Price above the 'cloud' is supportive; below is weak. A strong uptrend doesn't mean it's cheap — stocks that have run up are usually more expensive.